Conventional treatment or autologous transplantation has not been able to achieve long-term remission in patients with multiple myeloma (MM). Nonmyeloablative allogeneic transplantation might offer an option for cure without the high mortality associated with conventional conditioning. Here we present a retrospective analysis of patients with high-risk MM treated with nonmyeloablative allogeneic transplantation. In all, 52 patients with relapsed MM or high-risk features at diagnosis received 2 Gy TBI alone (n ¼ 3) or with fludarabine (n ¼ 49) as conditioning. Patients were heavily pretreated with a median of eight cycles of conventional chemotherapy and one or more autologous transplants for all but one patient. Regimen-related toxicity was low. Acute graft-versus-host disease II-IV occurred in 37% of patients, and 70% experienced chronic graft-versus-host disease (cGvHD). Median follow-up was 567 days, and transplant-related mortality was 17% in total. Estimated progression-free and overall survival at 18 months was 29.4 and 41.1%, respectively. Patients with cGvHD had a significantly higher progression-free survival, as did patients with up to eight cycles of pretreatment chemotherapy vs those with nine or more. In this highly pretreated patient group, disease control was unsatisfactory and our results suggest that a potential strategy might be to perform allogeneic transplant earlier in the course of the disease. Bone Marrow Transplantation (2005) 36, 963-969.
remains unsatisfactory. Autologous transplant has been shown to improve long-term survival, but is not able to achieve long-term cure. [1] [2] [3] [4] Once relapse has occurred, survival is limited despite the use of novel drugs and salvage regimens. [5] [6] [7] [8] Certain risk factors such as elevated b2-microglobulin, low albumin and/or deletion 13 at diagnosis have been reported to be associated with poor prognosis. [9] [10] [11] [12] [13] Allogeneic transplantation seems to offer an option for cure in myeloma. Bensinger et al 14 have shown longterm disease-free survival of over 10 years. Allogeneic transplantation offers the advantages of a tumor-free graft and the potential of a graft-versus-myeloma effect. The latter has been demonstrated by the administration of donor lymphocyte infusions for treatment of relapse following allogeneic transplantation. [15] [16] [17] Conventional allogeneic transplantation is limited by high transplant-related morbidity and mortality associated with myeloablative conditioning regimens. Some studies have shown treatmentrelated mortality (TRM) as high as 40%. [18] [19] [20] Nonmyeloablative transplantation has been reported to reduce regimen-related toxicity while maintaining the graftversus-tumor effect. Reduced pretransplant conditioning has been combined with post transplant immunosuppression to prevent graft rejection and control graft-versus-host disease (GvHD). This approach has been shown to be effective in leukemias and lymphomas. [21] [22] [23] [24] [25] [26] Recently, this strategy has been employed for patients with MM. 14, [27] [28] [29] [30] The initial reports in small groups of patients with shortterm follow-up indicated that encouraging outcome could be achieved, but the long-term benefit of this treatment modality has not yet been proven.
We have retrospectively analyzed the data of MM patients treated at our center with reduced conditioning and allogeneic stem cell transplantation (SCT).
Patients and methods

Patient characteristics
Between 09/99 and 06/03 at the University of Heidelberg, Germany, 52 patients with MM received a nonmyeloablative allogeneic transplantation. All patients gave written informed consent. Patient characteristics are shown in Table 1 .
Nine patients with high-risk features such as chromosome 13 abnormalities in FISH analysis (n ¼ 6), elevation of b2-microglobulin (43.0 mg/l) (n ¼ 2) or peripheral plasma cells (n ¼ 1) received an allogeneic SCT as part of first-line therapy. For three patients, the indication for allogeneic SCT was progression before the first auto-SCT. The remaining 40 patients were enrolled in our allogeneic transplant program later on in the course of disease as part of salvage therapy as they suffered from first or higher relapse of MM.
Median disease duration, measured from the date of diagnosis until allogeneic transplant was 35 months (8-233). A total of 29 patients had received one cycle of high-dose chemotherapy with autologous transplantation previously and 22 patients had received two or more. The median number of previous cycles of conventional chemotherapy was 8. In total, 34 patients were pretreated with more than eight cycles, and 18 with eight or less ( Table 1) . Pretreatment regimens included melphalan/ prednisone or dexamethasone in 23% of patients, 73% had received thalidomide-containing regimens, 90% had received anthracycline-containing regimens and 94% had received cyclophosphamide-or ifosfamide-based mobilization regimens.
The conditioning regimen consisted of fludarabine (3 Â 30 mg/m 2 day À4 to À2) in combination with 2 Gy TBI (day 0) for 49 patients, and the remaining patients received 210 cGy TBI (day 0) alone (n ¼ 3) (Table 2) .
Histocompatibility
HLA-A and -B typing was performed serologically or on a molecular basis; HLA-DRB1 was tested on a molecular basis. In all, 32 patients had related donors, of whom 26 were fully matched the others had one mismatch. All related donors were siblings, except for one donor who was a patient's child and had one mismatch. A total of 20 patients had matched unrelated donors ( Table 2) .
Graft
In five patients, the cell source was bone marrow (BM), the remaining patients received unmanipulated peripheral blood stem cells (PBSC). In six patients, T-cell content was adjusted to 1 Â 10 5 ( Table 2) .
Graft-versus-host disease
For GvHD prophylaxis, patients were given cyclosporine (CSP) in combination with mycophenalate mofetil (MMF). Cyclosporine trough levels (target level 200-400 mg/l) were measured by immunoassay and dosages were adapted accordingly. If no signs of GvHD were present, cyclosporine was tapered and discontinued by day 180. MMF was given until day 27. Patients with acute GvHD (aGvHD) were treated initially with prednisone, and additional immunosuppressive agents were added in refractory cases. aGvHD was graded according to Glucksberg criteria. 31 Chronic GvHD (cGvHD) was graded according to standard criteria and treated with immunosuppressive agents. 32 
Chimerism analysis
Absence of donor in chimerism analysis was defined as graft failure. Chimerism analysis was performed on day 28, day 56, day 100, day 200 and every 6 months thereafter using the following method: small tandem repeat amplification and analysis were performed by PCR from BM or peripheral blood samples using the AmpFISTR Profiler PCR amplification kit (Applied Biosystems, Weiterstadt, Germany) as recommended by the manufacturer. Separation and detection of the amplified PCR products were performed on an ABI 310 automated sequencer (Applied Biosystems). The analysis of results was performed using the Genescan 2.1 software (Applied Biosystems).
Evaluation of response
Disease status was determined according to the European Group for Blood and Marrow Transplantation (EBMT) criteria. 33 Briefly, complete remission (CR) required a disappearance of monoclonal gammopathy in both serum and urine, as determined by immunofixation for at least 6 weeks, and less than 5% plasma cells in a BM aspirate. Partial remission (PR) was defined as more than 50% reduction and minor response (MR) more than 25% reduction of the paraprotein level, respectively. No change (NC) was defined as less than 25% decrease or increase in the paraprotein level. Progressive disease (PD) was defined as the recurrence of monoclonal protein or BM plasmocytosis in the case of prior CR. The progression of non-CR patients required at least a 25% increase of paraprotein or development of new bone lesions.
Supportive care
Patients received anti-bacterial, anti-viral and anti-fungal prophylaxis during the period of immunosuppression. Intravenous broad-spectrum antibiotics were given whenever a patient developed fever 438.51C or clinical signs of infection. Patients were screened weekly for CMV-DNA and treated pre-emptively if needed. Blood and platelet transfusions were given according to standards of care.
Statistical analysis
TRM was defined as death related to the transplant procedure. Progression-free survival (PFS) was defined as the time from transplantation until disease progression, relapse or death from any cause. Overall survival (OS) was defined as the time from transplantation until death. The median duration of follow-up was calculated according to the method of Korn. 34 The Kaplan-Meier method was used to estimate the distribution of OS and PFS. 35 Confidence interval estimation was based on the cumulative hazard function using Greenwood's formula for standard error estimation. An Andersen-Gill regression model was used to analyze the effect of the time-depending covariates aGvHD and cGvHD on OS and PFS. 36 For the analysis of the effect on progressive disease, we considered death before progression/relapse (death in remission) as censoring. The proportional-hazards regression model of Cox was used to test the effect of possibly prognostic factors on the time to disease progression. The comparison of the distribution of the number of pretreatment cycles according to the response to treatment was performed using an exact two-sided Wilcoxon's rank-sum test. An effect was considered to be statistically significant if the corresponding P-value was 0.05 or less. The statistical analyses were performed using the statistical software package R, version 1.9.1. 37 
Results
Engraftment and transplant-related toxicity
PFS and OS
The estimated median follow-up duration of survivors was 479 days. The estimated median follow-up duration for all patients was 567 days. At the time of analysis, 24 patients remained alive. One patient was lost to follow-up when she moved outside the country on day 480 post transplant. Of those who were alive, nine patients were in CR, seven in PR and two had achieved MR. The Kaplan-Meier estimate of PFS is shown in Figure 1 . At 18 months, the estimated PFS rate was 29.4% (95% confidence limits: 0.18-0.47). In total, disease progression occurred in 29 (56%) of patients. Five patients (10%) died in remission, and for one patient, no response data were available. TRM was 17% in total, and the estimated cumulative incidence of TRM by day 100 was 4% (95% confidence interval 0-9%). Causes of death are shown in Table 3 . Kaplan-Meier estimate of OS was 41.1% at 18 months post transplant (Figure 2) . When analyzing the effect of cGvHD on PFS as a time-dependent variable, there was a significant advantage for patients with cGvHD (estimated hazard ratio 0.31, 95% confidence interval 0.12-0.78, P ¼ 0.01) ( Figure 3 ). aGvHD had no statistically significant influence on OAS or PFS when comparing no aGvHD vs aGvHD I-II or III-IV.
We then analyzed the influence of prognostic factors 'upfront treatment vs relapse', 'donor (related vs unrelated)', 'time from diagnosis to transplantation', 'the number of pretreatment cycles before transplantation' and 'exposure to high-dose chemotherapy' by multivariable Cox's regression. Only the number of cycles of pretreatment showed a statistically significant effect on PFS (P ¼ 0.02). The estimated hazard ratio of additional three cycles of chemotherapy before transplant is 1.30 with a 95% confidence interval CI95 ¼ (1.04, 1.63) . In Figure 4 , we illustrate this effect by showing the Kaplan-Meier estimates of PFS curves for patients who had received up to eight cycles of chemotherapy before transplant in comparison to those having received nine or more cycles of pretreatment.
When comparing patients with sustained disease response (PR or CR) to those who had progressive disease at any time following allogeneic transplant, those with response were shown to have a significantly lower number of cycles of pretreatment (exact Wilcoxon's rank-sum test: P ¼ 0.02; Figure 5 ). Nonmyeloablative transplantation for myeloma S Gerull et al
Discussion
In search for a curative approach for MM, allogeneic transplantation has been explored during the past decade.
Early studies with conventional myeloablative conditioning regimens suggested that long-term remission could be achieved at the cost of relatively high TRM of almost 50%. 19 Promising preliminary results have recently been reported with the development of reduced-intensity conditioning regimens, indicating that even elderly patients might benefit from allogeneic transplantation. 26 Some authors have in the mean time reported encouraging results using this strategy for patients with MM. 29, [38] [39] [40] We have adopted this strategy within our treatment algorithms for patients with high-risk factors or relapsed/refractory disease.
In accordance with published reports, 41, 29, 38 acute toxicity was low with a day 100 TRM of 4% and overall TRM of 17%. Periods of aplasia were short or even absent, and very few blood transfusions were needed. Engraftment was prompt and stable with 90% having 490% donor chimerism on day þ 56, and only one case of graft failure. The latter patient had not received a previous autologous transplant and was also one of the three patients who received 210 cGy alone as conditioning regimen. Storb et al 26 described a higher rate of graft failure for patients who were treated with 2 Gy TBI alone as conditioning regimen vs those who received fludarabine and TBI.
We observed an aGvHD rate of 37% Grade II-IV, and 24% Grade III-IV. cGvHD occurred in 70% of evaluable patients. Four patients died of aGvHD and one of cGvHD. The occurrence of aGvHD was not associated with improved OS or PFS. Earlier publications from our group have shown that severe GvHD following nonmyeloablative allogeneic transplantation in myeloma patients might be associated with response. 42 A significant difference in PFS in favor of those patients who experienced cGvHD was found in this analysis. Recently, a correlation between cGvHD and remission in myeloma patients has been reported by other groups. In a group of 22 patients, Einsele et al 41 observed an association between cGvHD and disease response, which resulted in improved event-free survival. This observation was also confirmed by Mohty et al, 30 and might be indicative of a graft-versus-myeloma effect. Interestingly, Pe´rez-Simon et al 43 have also reported that aGvHD was not associated with better outcome, whereas cGvHD was.
We observed an OS estimate of 41.1% at 18 months and a PFS estimate of 29.4% at 18 months. Of the 24 surviving patients, nine were in CR and seven in PR. In all, 17 patients died of progressive disease. As all patients were heavily pretreated, this outcome was favorable. The median disease duration until allogeneic transplant was 35 months, longer than in any other series of patients with MM reported. Of course, the varying intensity of the multiple pretreatment regimens that patients received was difficult to quantify, nevertheless the amount of pretreatment in terms of number of cycles of chemotherapy regimens administered has been shown to have a negative effect on PFS. This is also reflected by the fact that those patients who showed a sustained response to allogeneic transplant received significantly fewer cycles of pretreatment as compared to those who experienced progressive disease.
The observation that the number of cycles of pretreatment and employing allogeneic transplant as part of second-or third-line treatment vs first-line treatment have an adverse effect on long-term outcome has already been reported using conventional conditioning regimens for myeloma patients. 19, 20 With reduced-intensity conditioning in the present study, this correlation between intensity of previous treatment and long-term outcome of allogeneic transplantation has been confirmed. Kroger et al performed an analysis on the influence of timing of dose reduced allogeneic transplantation in MM and showed that relapse to prior high-dose therapy was the most significant factor influencing TRM and OS. 44 Using a nonmyeloablative conditioning regimen in 54 patients with MM who received an autologous transplant prior to allogeneic transplantation, Maloney et al have reported a PFS rate of 55% and an OS rate of 75% at 24 months. The median disease duration until transplant was 282 days at the time of the autologous transplant and the patients had received a median of four cycles of conventional chemotherapy. 29 Kroger et al 28 also evaluated the auto/allo sequential approach in 17 patients using a melphalan-containing regimen for allografting. The median time to autologous transplant was only 13 months. The estimated disease-free survival and OS at 2 years was 56 and 78%, respectively. Thus, the patients in these two studies were far less heavily pretreated than in our series and included more patients who were treated with allogeneic transplantation as part of first-line therapy than the present group we analyzed. This difference in observed survival rate also underlined our observation that pretreatment has a significant adverse effect on outcome. In addition, all patients in these two studies were treated with autologous transplantation prior to allogeneic transplant as part of an auto-allo sequential approach. This makes it difficult to separate which proportion of the antitumor effect must be attributed to the autologous transplant vs the Nonmyeloablative transplantation for myeloma S Gerull et al allogeneic transplant. Also, in the patient group reported by Kroger et al, patients received a melphalan-containing conditioning regimen that might also have contributed to the improved results. In our series, all but one of the patients had been pretreated with one or more regimens of high-dose melphalan followed by autologous transplantation and a majority had relapsed following this treatment, which is why a nonmyeloablative regimen was chosen.
Einsele et al 41 reported a follow-up of 22 patients with progressive MM who underwent allogeneic transplant after reduced-intensity conditioning with fludarabine, cyclophosphamide, TBI and ATG. All patients had progressed after a previous autologous transplant and were heavily pretreated with four to 28 cycles of conventional chemotherapy. This series of patients appeared to be comparable to our group. The estimated event-free survival and OS at 24 months was 22 and 25.5%, respectively, which is more consistent with our observation.
Despite all the caveats against the interpretation of a retrospective analysis, the short follow-up period and heterogeneous patient population, the following conclusions can be drawn. In highly pretreated patients, disease control following nonmyeloablative allogeneic transplantation has remained unsatisfactory. A possible future strategy is to perform allogeneic transplantation at an earlier stage of disease, for example, in combination with autologous transplant to assure optimal disease control before allogeneic transplantation. Future efforts should also concentrate on enhancing the graft-versus-myeloma effect that is reflected by the outcome advantage for patients with cGvHD. Owing to the morbidity and reduced quality of life that is often associated with extensive cGvHD, efforts should be targeted on promoting the graft-versus-myeloma effect while bringing the cGvHD under control.
